EGR2 and neoplasm: For CRC106, the final tumor masses were 1.46‐ and 1.83‐fold higher in KLF14‐deficient PDOX and 3.26‐ and 2.25‐fold higher in EGR2‐deficient PDOX compared to the scrambled control group (Figure 3F).